Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14041-

  Boura, Joana S ^a,b   Vance, Melisa ^a   Yin, Weihong ^a   Madeira, Catarina ^b   Lobato da Silva, Cláudia ^b   Porada, Christopher D ^a   Almeida Porada, Graça ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN; LENTIVIRUS VECTOR; TOLL LIKE RECEPTOR 9;

ARTICLE; BONE MARROW STROMA CELL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL;

EID: 84927763012     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.41     Document Type: Article

References (45)

1. 1 Bianco, P, Cao, X, Frenette, PS, Mao, JJ, Robey, PG, Simmons, PJ, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 19 (2013), 35–42.
2. 2 Caplan, AI, Correa, D, The MSC: an injury drugstore. Cell Stem Cell 9 (2011), 11–15.
3. 3 Prockop, DJ, Oh, JY, Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem 113 (2012), 1460–1469.
4. 4 Kramer, J, Dazzi, F, Dominici, M, Schlenke, P, Wagner, W, Clinical perspectives of mesenchymal stem cells. Stem Cells Int, 2012, 2012, 684827.
5. 5 Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I, et al., Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008), 1579–1586.
6. 6 Allison, M, Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27 (2009), 966–967.
7. 7 Carosella, ED, The tolerogenic molecule HLA-G. Immunol Lett 138 (2011), 22–24.
8. 8 Carosella, ED, Gregori, S, Rouas-Freiss, N, LeMaoult, J, Menier, C, Favier, B, The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 68 (2011), 353–368.
9. 9 Fainardi, E, Castellazzi, M, Stignani, M, Morandi, F, Sana, G, Gonzalez, R, et al. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci 68 (2011), 433–451.
10. 10 Nasef, A, Mathieu, N, Chapel, A, Frick, J, François, S, Mazurier, C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84 (2007), 231–237.
11. 11 Deschaseaux, F, Delgado, D, Pistoia, V, Giuliani, M, Morandi, F, Durrbach, A, HLA-G in organ transplantation: towards clinical applications. Cell Mol Life Sci 68 (2011), 397–404.
12. 12 Chiusolo, P, Bellesi, S, Piccirillo, N, Giammarco, S, Marietti, S, De Ritis, D, et al. The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone Marrow Transplant 47 (2012), 120–124.
13. 13 Naji, A, Rouas-Freiss, N, Durrbach, A, Carosella, ED, Sensébé, L, Deschaseaux, F, Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 31 (2013), 2296–2303.
14. 14 Spaggiari, GM, Capobianco, A, Becchetti, S, Mingari, MC, Moretta, L, Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006), 1484–1490.
15. 15 Crop, MJ, Korevaar, SS, de Kuiper, R, IJzermans, JN, van Besouw, NM, Baan, CC, et al. Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. Cell Transplant 20 (2011), 1547–1559.
16. 16 Soland, MA, Bego, MG, Colletti, E, Porada, CD, Zanjani, ED, St Jeor, S, et al. Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins. PLoS One, 7, 2012, e36163.
17. 17 Ankrum, JA, Ong, JF, Karp, JM, Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol, 2014.
18. 18 Kay, MA, Glorioso, JC, Naldini, L, Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7 (2001), 33–40.
19. 19 Ginn, SL, Alexander, IE, Edelstein, ML, Abedi, MR, Wixon, J, Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 15 (2013), 65–77.
20. 20 Patel, SA, Meyer, JR, Greco, SJ, Corcoran, KE, Bryan, M, Rameshwar, P, Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184 (2010), 5885–5894.
21. 21 Barber, DF, Long, EO, Coexpression of CD58 or CD48 with intercellular adhesion molecule 1 on target cells enhances adhesion of resting NK cells. J Immunol 170 (2003), 294–299.
22. 22 Gobin, SJ, van den Elsen, PJ, Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 61 (2000), 1102–1107.
23. 23 Kanzler, H, Barrat, FJ, Hessel, EM, Coffman, RL, Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13 (2007), 552–559.
24. 24 Gebler, A, Zabel, O, Seliger, B, The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 18 (2012), 128–134.
25. 25 Kay, MA, State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12 (2011), 316–328.
26. 26 Aslan, H, Zilberman, Y, Arbeli, V, Sheyn, D, Matan, Y, Liebergall, M, et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 12 (2006), 877–889.
27. 27 Aluigi, M, Fogli, M, Curti, A, Isidori, A, Gruppioni, E, Chiodoni, C, et al. Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24 (2006), 454–461.
28. 28 Haleem-Smith, H, Derfoul, A, Okafor, C, Tuli, R, Olsen, D, Hall, DJ, et al. Optimization of high-efficiency transfection of adult human mesenchymal stem cells in vitro. Mol Biotechnol 30 (2005), 9–20.
29. 29 Maurisse, R, De Semir, D, Emamekhoo, H, Bedayat, B, Abdolmohammadi, A, Parsi, H, et al. Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol, 10, 2010, 9.
30. 30 Kay, MA, He, CY, Chen, ZY, A robust system for production of minicircle DNA vectors. Nat Biotechnol 28 (2010), 1287–1289.
31. 31 Gill, DR, Pringle, IA, Hyde, SC, Progress and prospects: the design and production of plasmid vectors. Gene Ther 16 (2009), 165–171.
32. 32 Mairhofer, J, Grabherr, R, Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol 39 (2008), 97–104.
33. 33 Walker, WE, Booth, CJ, Goldstein, DR, TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome:DNA. Mol Ther 18 (2010), 775–784.
34. 34 Madeira, C, Ribeiro, SC, Pinheiro, IS, Martins, SA, Andrade, PZ, da Silva, CL, et al. Gene delivery to human bone marrow mesenchymal stem cells by microporation. J Biotechnol 151 (2011), 130–136.
35. 35 Hwa Cho, H, Bae, YC, Jung, JS, Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24 (2006), 2744–2752.
36. 36 Liotta, F, Angeli, R, Cosmi, L, Filì, L, Manuelli, C, Frosali, F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26 (2008), 279–289.
37. 37 Delarosa, O, Dalemans, W, Lombardo, E, Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol, 3, 2012, 182.
38. 38 Raicevic, G, Rouas, R, Najar, M, Stordeur, P, Boufker, HI, Bron, D, et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 71 (2010), 235–244.
39. 39 Romieu-Mourez, R, François, M, Boivin, MN, Bouchentouf, M, Spaner, DE, Galipeau, J, Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 182 (2009), 7963–7973.
40. 40 Giuliani, M, Bennaceur-Griscelli, A, Nanbakhsh, A, Oudrhiri, N, Chouaib, S, Azzarone, B, et al. TLR ligands stimulation protects MSC from NK killing. Stem Cells 32 (2014), 290–300.
41. 41 Waterman, RS, Tomchuck, SL, Henkle, SL, Betancourt, AM, A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One, 5, 2010, e10088.
42. 42 Nurmenniemi, S, Kuvaja, P, Lehtonen, S, Tiuraniemi, S, Alahuhta, I, Mattila, RK, et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res 316 (2010), 2676–2682.
43. 43 Wang, X, Moghimi, B, Zolotukhin, I, Morel, LM, Cao, O, Herzog, RW, Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol Ther 22 (2014), 1139–1150.
44. 44 Chamberlain, J, Yamagami, T, Colletti, E, Theise, ND, Desai, J, Frias, A, et al. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 46 (2007), 1935–1945.
45. 45 Gong, JH, Maki, G, Klingemann, HG, Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8 (1994), 652–658.